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Bisphosphonates (BPs) are widely used for the treatment of a range of conditions involving bone, such 
as osteoporosis and bone metastases of cancer, and their efficacy has been confirmed. Nevertheless, a first 
case of bisphosphonate-related osteonecrosis of the jaw (BRONJ) as an adverse effect of BP treatment was 
reported in 2003, and several clinical studies since then have elaborated the risk, prevention and treatment 
of BRONJ or bisphosphonate-related osteomyelitis of the jaw (BROMJ). However, effective decision 
making on BP risk is hampered by a lack of accurate information for patients, physicians or dentists. 
Furthermore, the narrow definition of BRONJ used to date has precluded the wider development of clinical 
research on risk.  
   In this review, we discuss current issues in BROMJ, with a focus on risk, prevention and treatment. In 
particular, we reconsider the definition of BRONJ from the standpoint of clinical evidence. Finally, we 
propose a new strategy for the treatment of BROMJ. 
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Bisphosphonate (BPs) are widely used for the prevention and treatment of a range of bone conditions, 
including postmenopausal osteoporosis, Paget disease, hypercalcemia in malignancies, and osteolytic bone 
metastases of cancer or multiple myeloma [1, 2]. BPs can be administered orally and intravenously in a 
wide range of doses, dosing intervals, and duration of administration [1]. The biologic action of BPs is to 
suppress farnesyl pyrophosphate synthase in the mevalonate biosynthetic pathway and inhibit the resorption 
of bone via the inactivation of osteoclasts [3]. Although this action accounts for the preventive or 
therapeutic efficacy of these agents, it also accounts for their uncommon skeletal-related events (SRE) or 
adverse effects [1, 2]. In particular, cases of osteonecrosis of the jaw (ONJ) have been reported as possible 
adverse effect of BPs since 2003 [4]. This condition is presently defined by the presence of exposed bone 
in the maxillofacial region for six to eight weeks [5-10], and patients with ONJ often encounter difficulties 
in sustaining their quality of life (QOL) [11].  
Due to a lack of information, BP-related ONJ (BRONJ) was initially considered difficult to treat, 
similarly to osteoradionecrosis of the jaw, and to be a largely different condition to osteomyelitis of the jaw 
(OMJ) [4, 12, 13]. Regrettably, however, a number of organizations, national regulatory agencies, medical 
specialty societies and clinicians disseminated information on the risk of BPs for ONJ without accurate data 
on incidence, risk factors, prognosis, or treatment [14], and thereby confounded both patients treated with 
BPs and medical and dental professionals. Many relevant studies and reviews have since appeared, however, 
and these early problems have been progressively resolved. 
In this paper, we review clinical studies of BRONJ or BP-related OMJ (BROMJ) over the last 10 years, 
outline the problems identified, and then discuss current issues in BRONJ and BROMJ, with a focus on 
risk, prevention and treatment. In particular, we discuss the definition of BRONJ from the standpoint of 





Literature search strategy and research questions 
A systematic search of the English literature was conducted. The MEDLINE/PUBMED and Scopus 
databases were searched from January 1, 2003 to December 31, 2012. In the MEDLINE search, we entered 
the following Medical Subject Headings (MeSH): "diphosphonates"[MeSH Terms] OR 
"diphosphonates"[All Fields] OR "bisphosphonate"[All Fields] OR "bisphosphonate-associated 
osteonecrosis of the jaw"[MeSH Terms] OR "bisphosphonate-associated"[All Fields] AND ("jaw"[MeSH 
Terms] OR "jaw"[All Fields]) AND (hasabstract[text] AND "humans"[MeSH Terms] AND English[lang])). 
We additionally searched studies published from January 1, 2012 to December 31, 2012 in the Scopus 
database by using the following key words: (TITLE-ABS-KEY-AUTH("osteonecrosis of the jaw" 
OR "osteomyelitis of the jaw" OR "inflammation of the jaw") AND (LIMIT-TO(PUBYEAR,2012)) 
AND (LIMIT-TO(LANGUAGE, "English")). 
Titles and abstracts were reviewed to determine relevance. The search for clinical evidence included 
randomized controlled trials (RCT), cohort studies, case-control studies, cross-sectional studies, case series 
and literature reviews. Letters, animal studies and basic studies were excluded. 
   Our research questions in the review were as follows: 
1. How much of the absolute risk of BROMJ is estimated to be accounted for by users of intravenous BPs? 
2. How much of the absolute risk of BROMJ is estimated to be accounted for by users of oral BPs? 
3. How much of the relative risk of OMJ is estimated by the incidence of OMJ in BPs users compared to 
non-users, regardless of BP type? 
4. What are the risk factors of BROMJ? 
5. Are there any prognosis markers for the incidence of BROMJ? 
6. Are there any effective preventive measures for the incidence of BROMJ? 
7. Are there any effective treatments for BROMJ? 
8. Are there any new treatments for BROMJ? 
   In the review, we investigated the following information: year of electronic publication, country, setting, 
type of study, target population and number, main endpoint, diagnostician, type of BP, search procedure of 
BPs, risk index, risk ratio, risk factors, prognosis, and treatments. In addition, the evidence grade of studies 
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was classified according to the 2010 American Heart Association guideline [15]. Here, we define meta-
analyses as evidence 1a, RCTs as 1b, cohort studies as 2, and case-control studies as 3. 
   A unit of incidence rates was converted into the unit “per million person-years”. All statistical analyses 




Results and Discussion 
Definition of epidemiological terms 
To aid understanding of this literature review, we first explain the epidemiological terms cumulative 
incidence, prevalence, incidence rate, absolute risk and relative risk, as follows.  
Cumulative incidence refers to the number or proportion of a group (cohort) of people who experience 
the onset of a health-related event during a specified time interval [16]. In contrast, prevalence refers to the 
total number of individuals who have an attribute or disease at a particular time or particular period divided 
by the population at risk of having the attribute or disease at that time or midway through the period, 
respectively [16]. Although the term “prevalence” is thus inherently different from “cumulative incidence” 
in meaning, we include “prevalence” in “cumulative incidence” here because of the severely limited 
number of cross-sectional studies identified in the literature review. In contrast, incidence rate refers to the 
rate at which a new event occurs in a population, and is quite different from “cumulative incidence”. 
Accordingly, we distinguish the term “incidence rate” from “cumulative incidence” in the review [16].    
These risks are then grouped as “absolute risk”, which means the number of events in a group divided 
by the total number of subjects in that group [16]. Moreover, we use the term “relative risk” to evaluate the 
risk of BPs for OMJ. This means the ratio of the risk of an event among the exposed to that among the 
unexposed [16]. 
 
History and Definitions of BROMJ 
In 2003, Marx first suggested a possible association between the use of intravenous BPs and avascular 
necrosis of the jaw [4], and described 36 patients receiving pamidronate or zoledronate who had exposure 
of necrotic bone in the oral cavity. Since this sensational report, hundreds of cases of BRONJ cases have 
been reported [17-30] and a number of clinical studies published between 2003 and 2006 demonstrated the 
absolute risk or risk factors of BRONJ among patients using intravenous BPs [31-38]. In the same period, 
the manufacturers or the US Food and Drug Administration indicated the presence of a safety concern 
regarding the use of BPs [14]. Furthermore, some expert panels recommended the prevention and treatment 
of BP-associated ONJ notwithstanding that evidence for the association was limited, particularly among 
users of oral BPs [19, 20, 39-41]. Finally, in 2007, a position paper by the American Association of Oral 
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and Maxillofacial Surgeons (AAOMS) proposed the establishment of BRONJ as a new disease entity with 
the following three characteristics: 1) current or previous treatment with a bisphosphonate; 2) exposed, 
necrotic bone in the maxillofacial region that has persisted for more than 8 weeks; and 3) no history of 
radiation therapy to the jaw [42]. Following this position paper, several associations stated definitions of 
BRONJ, BP-associated ONJ, or BP-ONJ which, despite the differences in naming, were commonly defined 
by the presence of exposed bone in the maxillofacial region [5-10, 43].  
Here, we propose grouping cases of OMJ together with ONJ, because we consider it difficult to 
distinguish ONJ from OMJ, for two reasons: first, radiographic findings in infected jawbone in patients 
treated with BPs are similar to those in BP-induced ONJ even if necrotic bone cannot be clinically 
visualized [44-46]; and second, the presence of osteonecrosis is a common histopathologic finding in both 
BP-induced ONJ and OMJ [47]. These finding suggest that the condition of bone exposure in the oral cavity 
is not always caused by avascular necrosis of the jaw. Several studies or reviews have also regarded ONJ 
as the same as OMJ [48-51]. We therefore need to reconsider the definition of “BRONJ” according to this 
recent clinical evidence and pathological findings of the condition; in particular, such early identification 
of OMJ without long-term exposure of necrotic bone may be relevant to treatment. 
 
How much of the absolute risk of BROMJ is estimated to be accounted for by users of intravenous BPs? 
Accumulated evidence has clarified that the risk of BROMJ is higher in patients taking intravenous BPs 
than oral BPs [37, 52-54]. In addition, most patients receiving intravenous BPs were considered to have 
cancer [7] and be at higher risk for infectious disease than those taking oral BPs. We therefore discuss 
incidence by route of administration.  
Table 1 show characteristics of the literature concerning cumulative risk of BROMJ among patients 
taking intravenous BPs. A total of 91 papers describing the cumulative risk of BROMJ were identified [10, 
31, 32, 34-37, 49, 53-135], the largest number of which came from the US, followed by Italy, Greece and 
other countries. Most studies were conducted in hospitals, and were aimed at investigating the cumulative 
incidence or risk factors of BROMJ. More than half of the 91 studies were cohort studies, although almost 
none of these had a control group, in other words patients who were not treated with BPs. Further, 21 of 
the 91 studies were conducted as RCTs, but with efficacy of BPs or SREs as main outcome, and the 
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incidence of BROMJ as a secondary endpoint only. The cumulative incidence of BROMJ in those studies 
ranged from 0% to 51.8%, or the incidence rate ranged from 0.70 per 100 patients to 5.5 per 1,000 person-
years.  
We summarized the characteristics of studies of BROMJ among patients taking intravenous BPs which 
had an evidence level of 3 or better (Table 2 and 3). The cumulative incidence of BROMJ in multicenter 
RCTs was extremely low, ranging from 0% to 3.5%, with a median incidence of 0.6% (Table 2). In contrast, 
the cumulative incidence of BROMJ in controlled, observational studies ranged from 0.34% to 14.8%, with 
a median incidence of 5.0% (Table 3). These findings appear to indicate a large difference between these 
studies in absolute risk.  
We speculate that the difference in absolute risk between studies is partly due to differences among the 
investigators of BROMJ in the various studies. In particular, the diagnostic criteria for BROMJ or the 
background of those diagnosing BROMJ was unclear in prospective studies because BROMJ was just one 
SRE or secondary endpoint. This might have resulted in underestimation of the incidence of BROMJ. In 
addition, we suspect that differences in the settings or target populations of the studies mainly influenced 
absolute risk; in other words, participants in the clinical trials may have been generally healthier than the 
subjects of the clinical observational studies. On the other hand, the subjects in clinical observational studies 
may have had several primary illnesses and required substantial medical treatment, including BPs. 
Moreover, differences between these studies may have resulted from differences in the duration of exposure 
to BPs, although we were unable to investigate duration in detail. To sum up, any interpretation of our 
results should be done with due regard to study design, setting, target population, sample size, definition of 
outcome, and diagnostician. 
   Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand. 
Several studies have shown the superiority of this agent to BPs in the treatment of bone metastases and 
prevention of SRE in cancer patients [105, 111, 112, 119, 134]. Notably, these studies have also indicated 
that denosumab has a similar risk for OMJ as BPs. The absolute risk of OMJ was estimated to range from 
0.8% to 2.3%. Given that evidence for the risk of OMJ with denosumab remains limited, however, particular 




How much of the absolute risk of BROMJ is estimated to be accounted for by users of oral BPs? 
The cumulative incidence of BROMJ in patients taking oral BPs ranged from 0% to 7.8% [10, 37, 51, 
54, 62, 106, 136-150], or the incidence rate ranged from 6.3 to 366 per million person-years [53, 146, 151, 
152]. We abstracted those studies with an evidence level of 3 or better (Table 4), among which cumulative 
incidence was estimated to range from 0% to 4.3%, or the incidence rate from 6.3 to 366 per million person-
years.  
Due to the low occurrence of BROMJ in patients treated with oral BPs, initial studies estimated 
incidence by anticipating the total number of individuals who had been prescribed oral BPs [62, 144]. More 
recently, however, population-based or larger hospital-based studies, as well as administrative data have 
allowed an understanding of the absolute risk of BROMJ in patients taking oral BPs [51, 53, 106, 146, 151, 
152]. From these studies and our previous study, the cumulative risk of OMJ with oral BPs is less than 1% 
in patients with osteoporosis, and the incidence risk is considered to be low.  
 
How much of the relative risk of OMJ is estimated by the incidence of OMJ in BPs users compared to non-
users, regardless of BP type? 
A meta-analysis which extracted data from 15 RCTs (n = 10,694) showed that treatment with zoledronic 
acid was significantly associated with the occurrence of ONJ (M-H pooled odds ratios (OR) = 3.2, 95% 
confidence interval (CI), 1.7–8) compared with no use [98]. In contrast, a meta-analysis of other data 
extracted from three RCTs (n = 736) showed no significant association between intravenous BPs and ONJ 
(pooled relative risks (RR) = 4.0, 95% CI, 0.44-35.8) [2]. Six observational studies reported the relative 
risk of BROMJ in patients treated with intravenous BPs while 10 observational studies reported the risk in 
patients treated with oral BPs (Table 5). The estimated OR, RR or hazard risks in patients treated with 
intravenous BPs ranged from 1.6 (95% CI, 0.71-3.8) to 299.5 (95% CI, 70-1282). Of these studies, only 
one found no significant association between intravenous BPs and OMJ [118], whereas the rest showed an 
increased risk of OMJ with intravenous BPs, with significance [37, 49, 52-54, 153]. Similarly, four studies 
found no significant or inverse association between oral BPs and OMJ [37, 53, 54, 154], whereas the rest 
showed an increased risk of OMJ with oral BPs, ranging from 2.2 (95% CI, 1.2-4.3) to 15.5 (95% CI, 6.0-
38.7) [50, 51, 146, 151-153]. Overall, both intravenous and oral BPs may increase the risk of OMJ, although 
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these studies slightly differed in endpoint characteristics (e.g. OMJ or Jaw surgery code), sample size, target 
population and number, and presence of adjustment for confounding. A conclusive answer awaits additional 
meta-analysis or larger clinical observational studies. 
 
What are the risk factors of BROMJ? 
More than one hundred studies have examined risk factors associated with BROMJ or prognosis. In 
particular, diabetes, cancer chemotherapy, corticosteroids, and thalidomide have all been suggested to be 
risk factors [31, 35, 50, 51, 53, 56, 60, 63, 70, 75, 86, 87, 110, 125, 128, 146, 153, 155-165]. Unfortunately, 
however, most of these studies evaluated risk factors without adjustment for confounding factors or controls, 
which may have introduced bias into judgment or decision-making. We therefore summarized the possible 
risk factors for BROMJ in controlled studies with consideration to potential confounding factors (Table 6). 
Most studies have shown that BPs with high potency or prolonged duration/no. of cycles increase the 
risk of BROMJ. These findings may be supported by the dose-response or strength association and 
coherence. On the other hand, findings for the association between other possible risk factors and BROMJ 
lack consistency. For example, some studies found an association between other possible risk factors such 
as use of cancer chemotherapy and BROMJ [50, 56, 60, 161], whereas others did not [54, 63, 70, 75, 110, 
153, 158, 160, 162]. Similarly, associations between other demographic factors such as sex, age or race and 
BROMJ are also controversial. With regard to oral status, many studies reported that the use of a denture, 
severe periodontal status, and surgical dental treatments such as tooth extraction may be risk factors of 
BROMJ, whereas others showed no significant association between periodontal status, caries, or root canal 
treatment and BROMJ. Overall, almost all these factors were investigated as possible confounding factors 
or secondary endpoints in the studies, but given that some surveys were conducted using questionnaires, 
interview, or chart review, and most definitions of factors were not described in detail, the accuracy of some 
diagnoses might have been low. In addition, many studies may have had insufficient statistical power to 
evaluate risk factors for BROMJ. These results should therefore be interpreted with care. Larger, well-





Are there any prognosis markers for the incidence of BROMJ? 
   C-terminal telopeptide (CTX) and other bone markers such as N-terminal telopeptide (NTX) or bone-
specific alkaline phosphatase (BAP) were first reported as possible prognostic markers of BROMJ in 2007 
[166]. Our review process identified seven relevant studies appearing since then [145, 167-173]. Among 
these, however, three studies were characterized as case series without controls [166-168] and the rest were 
case-control studies without adjustment for confounding factors [145, 169-173]. We were therefore unable 
to find sufficient evidence to support the hypothesis that suppression of CTX, NTX, BAP or other bone 
makers was a prognostic marker of BROMJ. One possibility is that although local bone turnover in the jaw 
might be suppressed, this local turnover has no impact on biochemical markers which reflect systemic bone 
turnover [172].  
With regard to genetic factors, nine studies have identified differences in genetic polymorphisms in 
case-control studies, and shown associations between some genes and the risk of BROMJ [73, 174-181]. 
These results suggest that the risk of BROMJ is increased by genes encoding for cytochrome P450 and 
aromatase, as well as RBMS3, IGFBP7, ABCC4, COL1A1, RANK, MMP2, OPG, OPN, CYP2C8, and 
NFAT2. These genes, which are associated with drug or bone metabolism, are possible prognosis markers 
of BROMJ, albeit that sample sizes in these studies were low [179, 180]. 
 
Are there any effective preventive measures for the incidence of BROMJ? 
A drug holiday from BPs has been reported to prevent BROMJ [5, 7]; in particular, one study found 
that a three-month washout period before surgical treatment prevented the incidence of BROMJ [166]. Here, 
however, we found no clinical evidence to support this hypothesis. Biologically, BPs are considered to 
accumulate in skeletal sites that have active bone remodeling, and to remain there for a long time [9, 47, 
152]. Present knowledge therefore provides little evidence to support the use of a three-month drug holiday 
to wash-out BPs from skeletal sites, and to support its clinical efficacy in the prevention of BROMJ. 
   Several reports investigated the effectiveness of oral care in the prevention of BROMJ [77, 82, 83, 182, 
183]. Although these studies were all conducted in single centers and did not consider other confounding 
factors, they nevertheless had sufficient sample sizes to examine the hypothesis, and all showed significant 
risk reductions by interventional preventive oral care. Although direct evidence that the severity of oral 
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hygiene or periodontal status increases the incidence of BROMJ remains limited [54, 162, 184], these 
reports suggest that poor oral hygiene and a severe periodontal status are risk factors for BROMJ and that 
dental care prevents the incidence of BROMJ. 
 
Are there any effective treatments for BROMJ? 
   Table 7 summarizes controlled studies which aimed to evaluate the treatment of BROMJ [79, 171, 185-
191]. Almost all studies demonstrated that surgical treatment was effective [186, 188-191]: while they 
differed in surgical treatment method, indications, and target populations, they all showed a common 
relationship between the presence of preoperative inflammation and prognosis of BROMJ, and found that 
successful treatment was more frequent when antibiotic therapy and/or oral care was provided before 
surgery. These results suggest that the control of local inflammation plays a crucial role in ensuring a 
positive prognosis for BROMJ after surgical treatment. 
One RCT showed that hyperbaric oxygen (HBO) therapy was effective for the treatment of BROMJ, as 
judged by a decrease in lesion size, number, and pain, and improvement in QOL [185]. Unfortunately, 
however, this study did not have a sufficient sample size (n = 49) to allow for adjustment of confounding 
factors. Two mechanisms for this effectiveness have been proposed. First, the produced reactive oxygen 
and nitrogen species signal osteoclast differentiation, activity and viability. Second, HBO therapy 
ameliorates edema and inflammation, augments microbial killing and invokes stem cell mobilization, 
vasculogenesis and tissue repair in other wounds [185]. Further large, well-designed controlled studies to 
investigate the effectiveness of surgical treatment or HBO therapy are required. 
 
Are there any new treatments for BROMJ? 
   Recent studies have reported that parathyroid hormone (teriparatide) is effective in in patients with 
BROMJ [192-198]. One of these studies was a case report and the rest were case series, however, and their 
level of clinical evidence was accordingly insufficient to confirm this efficacy. Interestingly, these studies 
did confirm the presence of bone regeneration in inflammatory regions at more than 2 months after 
subcutaneous injection of teriparatide into patients with BROMJ. The ongoing accumulation of case reports 
and case-series, or stronger evidence, might allow a better understanding of the pathogenesis of BROMJ 
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and a new approach to its treatment. 
 
Our proposal for the diagnosis, prevention and treatment of BROMJ in the early stage 
   From the accumulated clinical evidence in this review, we propose the following diagnosis, prevention 
and treatment strategy for BROMJ in the early stage (Figure 1). Compared to the AAOMS’s strategy in 
2009 [7], the four hierarchical diagnostic criteria defined below allow OMJ to be identified earlier, without 
the need for long-term exposure of necrotic bone [51]:  
1. possible cases are diagnosed by increased uptake on technetium bone scan with characteristic signs and 
symptoms of bone infection, and/or findings on dental panoramic X-ray.  
2. probable cases are diagnosed by imaging findings on computed tomography or magnetic resonance 
imaging scans which are consistent with findings of possible cases.  
3. confirmed cases are diagnosed by a histological picture consistent with OMJ and/or the isolation of 
microorganisms in samples obtained by extraoral open surgery, percutaneous biopsy of bone, excised bone 
or intramedullary tissue, or pus aspiration from adjacent tissues, with findings of probable cases  
4. cases which do not meet the above criteria are not considered as cases of OMJ.  
   Diagnosis of OMJ is often difficult, however, particularly in the early stage [199], and these criteria are 
not always consistently applied to different stages of OMJ. Osteomyelitis is caused by a certain inciting 
focus that enables the infection to propagate but has various clinical expressions, and the clinical 
characteristics and laboratory features of infection are not always present [199, 200]. This background 
explains why diagnostic imaging has long played a major role in the investigation of suspected 
osteomyelitis [201]. CT or MRI scans were of greater value in diagnosing OMJ than technetium bone scans 
or plain radiographs, but the highest priority was given to a histological picture consistent with OMJ and/or 
the isolation of a microorganism in samples [199-201]. 
The early identification of BROMJ using objective imaging or histological findings might also enable 
the use of more aggressive treatment, such as HBO therapy or surgical treatment if indicated, which might 





We conducted a systematic review of previous clinical studies of BROMJ over 10 years with a focus 
on risk, prevention and treatment. The still-accumulating evidence suggests that all types of BP increase 
the risk of OMJ incidence. Prevention of BROMJ might be aided by oral care before and after BP 
administration. Once a symptomatic condition in the jaw occurs, however, the use of technetium bone scan 
and CT or MRI findings may be useful in evaluating the condition in its early stage. After local 
inflammation is controlled with antibiotic therapy and/or oral care, surgical treatment may be valid. 
Biological and interventional studies suggest that HBO may be a useful adjunctive therapy during the 
disease course in encouraging bone remodeling and wound healing. Further investigations of the prevention 
and treatment of BROMJ in larger, prospective, well-designed controlled studies are required. 
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BPs = bisphosphonates; HBO = hyperbaric oxygen. 
Figure 1: Propose diagnostic criteria for OMJ 
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Table 1. Characteristics of studies of cumulative risk of bisphosphonate-related osteomyelitis of the jaw among patients taking intravenous bisphosphonates 
Published year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
No. of studies 0 0 2 4 14 18 14 9 17 13 
           
Country USA Italy Greece International Germany Canada Australia Japan Others 
No. of studies 24 18 8 7 6 4 4 3 19 
             
Setting Hospital Multi-center Single-center* Health insurance data Population-based Others 
No. of studies 55 20 6 6 2 2 
       
Type of study Meta-analysis RCT Cohort Cohort w/o control Case control Cross-sectional 
No. of studies 1 21 5 59 2 3 
           
Target population BC MM PC LC Cancer complex Osteoporosis or Paget disease Others 
No. of studies 18 15 8 2 37 5 6 
           
No. of population <100 100-500 500-1000 1000-5000 5000> 
No. of studies 28 28 10 15 10 
           
Main endpoint BROMJ SRE including BROMJ Codes of surgery or inflammation of the jaw 
No. of studies 47 39 5 
           
Diagnostician Surgeons or oncologists Dentists Physicians Investigators or committee Others Unclear 
No. of studies 35 17 3 14 2 20 
           
Search procedure From pharmacy or prescription records From medical or dental records Marketing information 
No. of studies 79 9 3 
         
Evidence grade 1a (meta-analysis) 1b (RCT) 2 or 3 (controlled study) 4 (quasi-experimental study) 
 No. of studies 1 21 7 62 
 publication lists 98 61, 69, 72, 80, 93, 96, 101, 104, 
105, 108, 111-113, 115, 116, 119, 
120, 122, 123, 134, 135 
37, 49, 53, 54, 106, 118, 133 10, 31, 32, 34-36, 55-60, 62-71, 73-79, 
81-92, 94, 95, 97, 99, 100, 102, 103, 




BC = breast cancer; BPs = Bisphosphonate; BROMJ = bisphosphonate-related osteomyelitis of the jaw; LC = lung cancer; MM = multiple myeloma; PC = prostate 
cancer; RCT = randomized clinical trial; SRE = skeletal-related events; w/o = without. 
* Studies were conducted in a single center, excluded hospitals.  
Table 2. Incidence of bisphosphonate-related osteomyelitis of the jaw among patients taking intravenous bisphosphonates in studies with an evidence level of 1 
No. Author Setting Target Kind of BP 
End 
point* 
Diagnosis Outcomes/users Incidence (%) Evidence 
98 Mauri N.A. BC P, ZA, I, C, R 0 unclear 13/3,987 0.2  1a 
61 Lyles MC HF ZA 1 physicians 0/1,054 0.0  1b 
69 Grbric MC OSP ZA 1 AC 1/3,875 0.03  1b 
72 Brufsky MC BC ZA 1 unclear 0/1,652 0.0  1b 
80 Musto MC MM ZA 1 unclear 1/81 1.2  1b 
93 Hines SC BC ZA 1 OMS 1//274 0.4  1b 
96 Brufsky MC BC ZA 1 AC of ONJ  0/301 0.0  1b 
101 Guarneri MC BC 
 P, ZA, C 
with BV 
1 unclear 2/233-10/425 0.9-2.4 1b 
104 Gimsing MC MM P 1 questionnaire 
30mg: 2/252,  
90mg: 8/250 
30mg: 0.8, 
90mg: 3.2  
1b 




DMAB: 2.0  
1b 






111 Henry MC CA, MM ZA, DMAB 1 AC of ONJ 





112 Fizazi MC PC ZA, DMAB 1 AC 





113 Coleman MC BC ZA 1 investigators 11/1,590 0.7  1b 
115 Gnant MC BC ZA 1 
investigators or 
patients level 
0/900 0.0  1b 
116 Pivot SC BC I 1 
investigators or 
patients level 
2/334 0.6  1b 
119 Saad MC CA, MM ZA, DMAB 1 







120 Brufsky MC BC ZA 1 
investigators and 
AC of ONJ 
0/602 0.0  1b 
122 Coleman MC BC ZA 1 investigators 17/1,686 1.1  1b 
123 Safra SC BC ZA 1 investigators 0/47 0.0  1b 
134 Scagliotti MC LC ZA, DMAB 1 unclear 
ZA: 3/406, 
 DMAB: 3/395 
ZA: 0.7, 
DMAB: 0.8  
1b 
135 Scagliotti MC LC ZA 1 investigators 1/226 0.4 1b 
AC = adjudication committee; BC = breast cancer; BPs = bisphosphonates; BV = bevacizumab; C = clodronate; CA = cancer patients; DMAB = denosumab; HF = 
hip fracture patients; I = ibandronate; LC = lung cancer; MC = multicenter; MM = multiple myeloma; N.A. = not applicable; OMS = oral and maxillofacial surgeons; 
ONJ = osteonecrosis of the jaw; OSP = osteoporosis; P = pamidronate; PC = prostate cancer; R = risedronate; SC = single center; ZA = zoledronic acid.  
* Endpoint 0 means ONJ and 1 means skeletal related events including ONJ. 
  
Table 3. Incidence of bisphosphonate-related osteomyelitis of the jaw among patients taking intravenous bisphosphonates in studies with an evidence level of 2 or 3 









(% or rate) 
Evidence 
37 Zavras HIP CA, MM P, ZA 2 ICD-9 code 20/5,850 0.34  2 
53 Tennis HIP CA I, P, ZA 0 
ICD-9 or CPT and 
chart review  
15/2,876 
5.3 per 1,000 
person-years 
2 
54 Yamazaki HOSP CA 
INC, P, 
ZA 
0 OMS 4/27 14.8† 2 
106 Skrepnek HIP CA, OSP P, ZA 2 ICD-9 code 
CA: 12/6,276,  




133 Beuselinck HOSP RCC ZA 1 patient level 5/49 9.6  2 
49 Wilkinson HIP CA P, ZA 2 ICD-9 code 95/14,349 
5.5 per 100 
patients 
3 
118 Baillargeon HIP OSP 
E, I, P, 
ZA 
2 ICD-9 code 9/2,296 
0.70 per 100 
patients 
3 
BPs = bisphosphonates; CA = cancer patients; CPT = current procedural terminology; E = etidronate; HIP = health insurance plan data; HOSP = hospital; I = 
ibandronate; INC = incadronate; ICD = international classification of diseases; MM = multiple myeloma; OMS = oral and maxillofacial surgeons; OSP = osteoporosis; 
P = pamidronate; RCC = renal cell carcinoma patients; ZA = zoledronic acid. 
* Endpoint 0 means osteonecrosis of the jaw (ONJ), 1 means skeletal related events including ONJ, and 2 means jaw surgery or inflammation of the jaw code. 
† Cumulative incidence of bisphosphonate-related osteonecrosis of the jaw after tooth extraction.  
Table 4. Incidence of bisphosphonate-related osteomyelitis of the jaw among patients taking oral bisphosphonates 
No. Author Setting 
Target 
population 
Kind of BP/ 








(% or rate) 
Evidence 
138 Wells N.A. PW A 1 review of RCTs N.A. 0 1a 
139 Wells N.A. PW R 1 review of RCTs N.A. 0 1a 
136 Jeffcoat HOSP 
OSP, 
OSPE  
A 1 dentists 0/355 0 1b 
149 Paterson MC BC C 1 investigators 1/1,662 0.06 1b 
37 Zavras HIP CA A, R 2 ICD-9 code 19/20,438 0.092  2 
51 Yamazaki HOSP OSP A, E, R 3 
ICD-10 and OMS 
chart review 
21-46/4,129 0.46-0.99 2 
53 Tennis HIP OSP A, E, I, R  0 
ICD-9 or CPT and 
chart review  
2/6,319 
150 per million 
person-years† 
2 
54 Yamazaki HOSP OSP A, E, R 0 OMS 1/99 1.0‡  2 
106 Skrepnek HIP CA, OSP A, E 2 ICD-9 code 
79/213,364- 
199/213,364 
0.02-0.09  2 
141 Sedghizadeh HOSP 
PT taking 
A 
A 0 dentists 9/208 4.3 2 




ICD-9 and chart 
review 
6/21,163 
6.3 per million 
person-years† 
2 
151 Etminan HIP OSP A, E, R 2 ICD-9 code 196/87,837 
267 per million 
person-years 
3 
152 Lapi BEST OSP PO 2 
ICD-9 and chart 
review  
61/65,220 
366 per million 
person-years† 
3 
A = alendronate; BEST = Bisphosphonates Effectiveness Safety Trade-off network; BC = breast cancer; BPs = bisphosphonates; C = clodronate; CA = cancer patients; 
CPT = current procedural terminology; E = etidronate; HIP = health insurance plan data; HP = Health Partners of Minnesota; HOSP = hospital; KPNW = Kaiser 
Permanente Northwest; I = ibandronate; ICD = international classification of diseases; MC = multicenter; N.A. = not applicable; OMS = oral and maxillofacial 
surgery; OSP = osteoporosis; OSPE = osteopenia; PO = per os; PT = patients; PW = postmenopausal women; R = risedronate; RCT; = randomized clinical trial. 
* Endpoint 0 means osteonecrosis of the jaw (ONJ), 1 means skeletal related events including ONJ, 2 means jaw surgery or inflammation of the jaw code, and 3 
means osteomyelitis of the jaw. 
† To convert an incidence rate to “per million person-years,” we simply multiplied. 
‡ Cumulative incidence of bisphosphonate-related ONJ after tooth extraction. 
  
Table 5. Relative risk of bisphosphonates for osteomyelitis of the jaw  
No. Author Setting 
Target 
population 












49 Wilkinson HIP CA IV 2 44,771 HR 11.5 [6.5-20.3] yes 3 





CA IV/PO 2 5,850 RR IV: 4.2 [2.7-6.7] 








2 714,217 OR IV: 4.5 [3.2-6.3] 
PO: 0.65 [0.54-0.79] 
no 3 




0 46,542 OR IV: 8.8 [2.0-38]  
PO: 0.15 [0.00-0.36] 
yes 2 
54 Yamazaki HOSP TE IV 
PO 
0 3,216 RR IV: 200.2 [23.8-1679] 
PO: 12.9 [0.82-204] 
yes 2 
153 Barasch PBRN CA+OSP IV 
PO 
2 764 OR IV: 299.5 [70-1282] 
PO: 12.2 [4.3-35] 
yes 3 
50 Vestergaard NR OSP PO 0 414,245 HR A: 3.2 [1.4-6.9] 
E: 2.2 [1.2-4.3] 
yes 3 
51 Yamazaki HOSP OSP PO 3 6,923 OR 5.0 [1.9-12.9] yes 2 
146 Fellows HIP HP, 
KPNW 
PO 0 572,606 OR 15.5 [6.0-38.7] no 2 
152 Lapi BEST  OSP PO 0 65,220 OR 2.8 [1.3-5.9] yes 3 
151 Etminan HIP OSP PO 2 87,837 RR A: 2.9 [1.7-5.1] 
E: 2.4 [1.0-5.6] 
yes 3 
R: 3.3 [1.0-10.6] 
154 Pazianas HIP OSP PO 2 3,505 OR 0.91 [0.70-1.19] yes 3 
A = alendronate; BEST = Bisphosphonates Effectiveness Safety Trade-off network; BPs = bisphosphonates; CA = cancer patients; E = etidronate; HIP = Health 
Insurance Plan data; HOSP = Hospital; HP = Health Partners of Minnesota; HR = hazard risk; I = ibandronate; IV = intravenous; NR = national registry of Danish 
population; OR = odds ratio; OSP = osteoporosis; P = pamidronate; PBRN = practice based research network; PO = per os; R = risedronate; RR = relative risk; TE 
= patients undergoing tooth extraction; ZA = zoledronic acid. 
* Endpoint 0 means osteonecrosis of the jaw (ONJ), 1 means skeletal related events including ONJ, 2 means jaw surgery or inflammation of the jaw code, and 3 
means osteomyelitis of the jaw. 
 
  
Table 6. Risk factors of bisphosphonate-related osteomyelitis of the jaw 
Risk factor Publication lists of controlled studies with adjustment for covariates 
 Positive association Negative association 
Gender 164 35, 49, 53, 54, 56, 60, 70, 71, 91, 100 
Age 38, 165 31, 49, 53, 54, 56, 70, 71, 75, 91, 100, 164 
Race 117, 165  
Smoking 125, 160 75, 91, 163 
Alcohol 167 54, 75, 160 
Primary illness   
  Diabetes 50, 125, 156, 159 56, 128, 110, 146, 160 
  Hypertension  56, 160 
Use of BPs   
Duration/cycle of BPs 31, 35, 36, 49, 57, 75, 91, 125, 153, 161, 164, 165, 168 50, 86, 87, 152, 154, 158  
BPs with high potency 31, 35, 36, 38, 49, 50, 52, 54, 75, 91, 125, 160, 164, 181 154, 158 
Use of other drugs   
Cancer chemotherapy 50, 56, 60, 161 54, 63, 70, 75, 110, 153, 158, 160, 162 
Corticosteroids 172 53, 54, 56, 70, 86, 110, 125, 128, 153, 158, 160 
  Thalidomide 35 31, 70, 71, 86, 110 
Oral status   
Tooth extraction 38, 70, 75, 91, 128, 153, 162, 163  
Periodontitis/Oral hygiene 54, 162 91,153, 159, 163  
Use of denture 91, 163, 167 128, 165 
BPs = bisphosphonates  
Table 7. Treatment of bisphosphonate-related osteomyelitis of the jaw  
ID Author Treatment Setting Target Kinds of BP Population 
no.  
Improvements Evidence 
185 Freiberger HBO therapy REC BRONJ P, ZA, A 46 time to healing, pain, QOL  1b 
79 Montefusco antibiotic prophylaxis v.s. 
none 
HOSP MM P, ZA 178 reduction of BRONJ incidence 2 
171 Atalay Laser-assisted v.s. 
conventional surgery 
HOSP BRONJ ZA 20 no statistically significant 
difference between two 
surgeries 
2 
186 Wutzl Surgical treatment HOSP BRONJ P, ZA, A, I, R 58 stages after surgery 2 
187 Gasparini Spiramycin v.s. ACA HOSP BRONJ unclear 25 clinical outcomes 2 
188 Vescovi Er:YAG laser surgery HOSP BRONJ unclear 91 clinical outcomes 2 
189 Vescovi Surgical treatment MC BRONJ P, ZA, A, others 567 clinical outcomes 2 
190 Vescovi Medical and surgical 
therapy 
HOSP BRONJ unclear 128 clinical outcomes 2 
191 Graziani Surgical intervention HOSP BRONJ P, ZA, A, C, I, 
N, R 
347 clinical outcomes* 3 
A = alendronate; ACA = amoxicillin and clavulanic acid; BPs = bisphosphonates; BRONJ = bisphosphonate-related osteonecrosis of the jaw; C = clodronate; E = 
etidronate; Er: YAG = erbium-doped yttrium aluminum garnet; HBO = hyperbaric oxygen; HOSP = Hospital; HR = hazard risk; I = ibandronate; IV = intravenous; 
MC = multicenter; MM = multiple myeloma; N = neridronate; P = pamidronate; PO = per os; QOL = quality of life; R = risedronate; REC = recruitment 
nationwide; ZA = zoledronic acid. 
* The result was estimated by odds ratios adjusted for age, gender, stage, and use of corticosteroids. 
 
